1. Get more info on this report!
The World Market for Diabetes Treatments
October 1, 2010
This Kalorama Information report , The World Market for Diabetes Treatments, provides
market estimates and forecasts for the world market for diabetes treatments. The
diabetes market is one of the fastest growing markets within the pharmaceutical sector,
and is one of the few pharmaceutical sectors that are likely to continue to grow at
double digit rates throughout the forecast period. Major contributing factors to growth
are increasing obesity and an aging worldwide population. The total market for diabetes
treatments is divided into two major segments:
Insulin Markets in US, Europe, Japan, ROW
Oral Hypoglycemics in US, Europe, Japan, ROW
For each of these market segments the report provides market share and regional
breakout (US, Europe, Asia, ROW). The report also discusses treatment for diabetes
complications and natural and herbal treatments.
The report’s geographic scope is worldwide with information for specific geographical
regions; world demographics; life expectancy by country, and other general issues
affecting the market. Trends covered in the report include:
New Products and the Development Pipeline (Afrezza, Bydureon, Syncria,
AVE0010, Balaglitazone, Metgluna Otelixizumab and others)
Transplantation Research Efforts
Β-Cell Transplantation Research
Potential New Drug for Type 2 Diabetes
Insulin Pills
Three-month Insulin Shot
Outsourcing of Diabetes Projects
Reclassification of Cause of Death
Information is presented as a worldwide overview, with special emphasis on the U.S.,
Europe, and other key markets.

2. A market summary includes market analysis by product and region and a competitive
analysis of leading providers. Additionally, key company profiles are included, including
profiles of the following:
Amylin Pharmaceuticals
AstraZeneca
GlaxoSmithKline
Eli Lilly & Co.
Merck
Metabolex, Inc.
Novo Nordisk A/S
Pfizer Inc.
Sanofi-Aventis Group
Takeda Pharmaceutical Company Limited
The information for this report was gathered using both primary and secondary research
including comprehensive research of secondary sources such as company literature,
databases, investment reports, and medical and business journals. Telephone
interviews and email correspondence were the primary method of gathering information.
For the purpose of this study, Kalorama Information conducted interviews with more
than 25 key industry officials, consultants, health care providers, and government
personnel. These sources were the primary basis in gathering information specifically
relating to revenue and market share data presented in this report. Additional interviews
were completed with relevant company representatives including marketing directors,
division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level. The base year
for data was 2009. Historical data was provided for the years 2008, with forecast data
provided for 2010 through 2015. Compound annual growth rates (CAGRs) are provided
for 2008-2015 periods for each region and/or segment covered. Competitive analysis is
provided for the year 2009. The forecasted market analysis for 2009-2015 was largely
based on demographic trends, new developments, innovative technology and global
expansion.
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
Background
Scope and Methodology
Size and Growth of the Market
Key Issues and Trends Affecting Market
Leading Competitors

3. CHAPTER TWO: INTRODUCTION
Background
Therapeutic Practices
France
Germany
Italy
Japan
Spain
United Kingdom
United States
China
India
CHAPTER THREE: CURRENT THERAPEUTICS FOR DIABETES
Insulin
o Regular Insulin
o Long-Acting and Basal Insulin
o Rapidly Acting Insulin
o Combinations
o Insulin Pumps
o Insulin Pens
o Inhaled Insulin
o Other Treatments
Oral Hypoglycemics
Sulfonylureas
o Biguanides
o á-Glucosidase Inhibitors
o Thiazolidinediones
o Meglitinides
o D-Phenylalanine Derivatives
o GLP1 Agonists
o DPP-IV Inhibitor
Current Therapeutics for Diabetic Complications
o Antihypertensive Therapy
o ACE Inhibitors
o á/â(Alpha/Beta)-Blockers
o Calcium Channel Blockers
o Diuretics
o Angiotensin II Receptor Antagonists
Dyslipidemia Therapy
HMG-CoA Reductase Inhibitors--Statins
Bile Acid Sequestrants

4. Fibric Acid Derivatives
Niacin
Cholesterol Absorption Inhibitors
Atherosclerosis Therapy
Arrhythmia Therapy
Peripheral Vascular Disease Therapy
CHAPTER THREE: TOTAL MARKET REVENUES, FORECAST AND COMPETITIVE
ANALYSIS
Total Worldwide Diabetes Market Analysis by Geographic Segment
Total Worldwide Diabetes Market Competitive Analysis
Total Worldwide Diabetes Market by Segment
Insulin
Oral Hypoglycemics
CHAPTER FOUR: KEY ISSUES, TRENDS AND DEVELOPMENTS
New Products and the Development Pipeline
o Afrezza
o Bydureon
o Syncria
o AVE0010 Once Daily and Twice Daily
o Balaglitazone
o Dapagliflozin and Dapagliflozin/Meformin Fixed Dose Combination
o Degludec and Degludec Plus
o Daimyd Vaccine
o Dutogliptin
o Glinsuma, Glufast, Metgluna
o MK 0431C
o Ondero
o Oral-lyn
o Otelixizumab
o Taspoglutide
Transplantation Research Efforts
o Â-Cell Transplantation Research
Potential New Drug for Type 2 Diabetes
Insulin Pills
Three-month Insulin Shot
Outsourcing of Diabetes Projects
Reclassification of Cause of Death
CHAPTER FIVE: NUTRITIONAL SUPPLEMENT AND HERBAL APPROACHES TO
THE TREATMENT OF DIABETES
Background

5. Nutritional Supplements
o Ascorbic Acid (Vitamin C)
o Biotin
o Chromium
o Copper
o Magnesium
o Niacin and Niacinamide
o Potassium
o Selenium
o Thiamine
o Vanadium
o Vitamin B6 (Pyridoxine)
o Vitamin B12
o Vitamin E
o Zinc
Nutritional Treatment of Diabetic Neuropathy
o Herbal Treatment of Diabetes
 Aloe (Various)
 Arctium lappa (Burdock Root)
 Allium cepa (Onion)
 Grifola frondosa (Maitake Mushroom)
 Mulberry
 Panax ginseng (Korean ginseng)
o Ayurvedic Medicine and Herbs
 Gymnema sylvestre (Asclepias germinata)
 Momordica charantia (Bitter Gourd)
 Trigonella foenum graecum (Fenugreek)
o Other Herbs with Significant Anti-Diabetic Effects
o Traditional Chinese Medicine
CHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS
First Conclusion
o Implications:
Second Conclusion
o Implications:
Third Conclusion
o Implications:
Fourth Conclusion
o Implications:
Fifth Conclusion
o Implications:
Sixth Conclusion
o Implications:
Seventh Conclusion
o Implications:

6. Eighth Conclusion
o Implications:
Ninth Conclusion
o Implications:
Tenth Conclusion
o Implications:
Eleventh Conclusion
o Implications:
Twelfth Conclusion
o Implications:
Thirteenth Conclusion
o Implications:
Fourteenth Conclusion
o Implications:
Fifteenth Conclusion
o Implications:
CHAPTER SEVEN: LEADING MANUFACTURERS
Overview
Amylin Pharmaceuticals
AstraZeneca
GlaxoSmithKline
Eli Lilly & Co.
Merck
Metabolex, Inc.
Novo Nordisk A/S
Pfizer Inc.
Sanofi-Aventis Group
Takeda Pharmaceutical Company Limited
Available immediately for Online Download at
http://www.marketresearch.com/product/display.asp?productid=2809047
US: 800.298.5699

7. UK +44.207.256.3920
Int'l: +1.240.747.3093
Fax: 240.747.3004